The potential beneficial effects of drugs on the immune response to vaccination

Seminars in Oncology

Volumn 39, Issue 3, 2012, Pages 340-347

  Liu, Wai M ^a   Dalgleish, Angus G ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOMODULATING AGENT; LENALIDOMIDE; POMALIDOMIDE; SUNITINIB; T LYMPHOCYTE RECEPTOR; THALIDOMIDE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BEHCET DISEASE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER THERAPY; DRUG POTENTIATION; ERYTHEMA NODOSUM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY METASTASIS; LEISHMANIASIS; LEPROSY; LOW DRUG DOSE; MYELOID PROGENITOR CELL; MYELOMA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 84861167937     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.02.012     Document Type: Article

References (83)

1. E.J. Small, P.F. Schellhammer, C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094 (Pubitemid 46638945)
2. C.S. Higano, P.F. Schellhammer, E.J. Small Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670 3679
3. R. Ramlau, E. Quoix, J. Rolski A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer J Thorac Oncol 3 2008 735-4
4. + T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients Int J Cancer 125 2009 1372 1379
5. + suppressor-inducer T-cells Cancer Res 48 1988 1671 1675 (Pubitemid 18091225)
6. T. Browder, C.E. Butterfield, B.M. Kräling Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 2000 1878 1886 (Pubitemid 30207647)
7. S.K. Teo, D.I. Stirling, J.B. Zeldis Thalidomide as a novel therapeutic agent: new uses for an old product Drug Discov Today 10 2005 107 114 (Pubitemid 40247808)
8. J.B. Bartlett, K. Dredge, A.G. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 2004 314 322 (Pubitemid 38525287)
9. L.G. Corral, P.A. Haslett, G.W. Muller Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha J Immunol 163 1999 380 386 (Pubitemid 29295864)
10. K. Dredge, J.B. Marriott, S.M. Todryk Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity J Immunol 168 2002 4914 4919 (Pubitemid 34495953)
11. J.B. Marriott, I.A. Clarke, K. Dredge Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells Clin Exp Immunol 130 2002 75 84
12. K. Dredge, J.B. Marriott, C.D. Macdonald Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects Br J Cancer 87 2002 1166 1172 (Pubitemid 35418112)
13. W.M. Liu, J.Y. Henry, B. Meyer Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs) Br J Cancer 101 2009 803 812
14. J.B. Marriott, S. Cookson, E. Carlin A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines AIDS Res Hum Retroviruses 13 1997 1625 1631 (Pubitemid 28009368)
15. P.A. Haslett, J.D. Klausner, S. Makonkawkeyoon Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients AIDS Res Hum Retroviruses 15 1999 1169 1179 (Pubitemid 29411802)
16. W.A. Hanekom, J. Hughes, P.A. Haslett The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children J Infect Dis 184 2001 1192 1196 (Pubitemid 33010474)
17. J.B. Zeldis, R. Knight, M. Hussein A review of the history, properties, and use of the immunomodulatory compound lenalidomide Ann N Y Acad Sci 1222 2011 76 82
18. L.M. Weiner, M.V. Dhodapkar, S. Ferrone Monoclonal antibodies for cancer immunotherapy Lancet 373 2009 1033 1040
19. + regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 2007 641 648 (Pubitemid 46348738)
20. S. Brode, A. Cooke Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide Crit Rev Immunol 28 2008 109 126 (Pubitemid 351507425)
21. G. Schiavoni, F. Mattei, T. Di Pucchio Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer Blood 95 2000 2024 2030 (Pubitemid 30151641)
22. D. Berd, H.C. Maguire Jr, M.J. Mastrangelo Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide Cancer Res 44 1984 5439 5443 (Pubitemid 15204525)
23. P.O. Livingston, S. Cunningham-Rundles, G. Marfleet Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma J Biol Response Mod 6 1987 392 403 (Pubitemid 17112189)
24. N. Matsushita, S.A. Pilon-Thomas, L.M. Martin Comparative methodologies of regulatory T cell depletion in a murine melanoma model J Immunol Methods 333 2008 167 179
25. A.K. Nowak, B.W. Robinson, R.A. Lake Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy Cancer Res 62 2002 2353 2358 (Pubitemid 34411717)
26. J.M. Plate, A.E. Plate, S. Shott Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas Cancer Immunol Immunother 54 2005 915 925 (Pubitemid 40991334)
27. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin Cancer Res 11 2005 6713 6721 (Pubitemid 41339014)
28. V. Bronte, E. Apolloni, A. Cabrelle Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells Blood 96 2000 3838 3846
29. Y. Huang, X. Chen, M.M. Dikov Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF Blood 110 2007 624 631 (Pubitemid 47105401)
30. S. Ostrand-Rosenberg, P. Sinha Myeloid-derived suppressor cells: linking inflammation and cancer J Immunol 182 2009 4499 4506
31. B. Almand, J.R. Resser, B. Lindman Clinical significance of defective dendritic cell differentiation in cancer Clin Cancer Res 6 2000 1755 1766 (Pubitemid 30305068)
32. N. Boissel, P. Rousselot, E. Raffoux Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate Leukemia 18 2004 1656 1661 (Pubitemid 39386344)
33. J.H. Finke, B. Rini, J. Ireland Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients Clin Cancer Res 14 2008 6674 6682
34. + dendritic cell frequency predicts progression-free survival Clin Cancer Res 14 2008 5884 5892
35. J.S. Ko, A.H. Zea, B.I. Rini Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clin Cancer Res 15 2009 2148 2157
36. J. Ozao-Choy, G. Ma, J. Kao The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies Cancer Res 69 2009 2514 2522
37. R.J. Motzer, B.I. Rini, R.M. Bukowski Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2006 2516 2524 (Pubitemid 43854967)
38. W.M. Liu Enhancing the cytotoxic activity of novel targeted therapies - is there a role for a combinatorial approach? Curr Clin Pharmacol 3 2008 108 117
39. R. Lord, S. Nair, A. Schache Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study J Urol 177 2007 2136 2140 (Pubitemid 46726410)
40. + T lymphocytes Clin Exp Immunol 150 2007 523 530 (Pubitemid 350098743)
41. B. Meyer, W.M. Liu, A. Dalgleish The role of Tregs in cancer: Foxp3 as a putative target for therapy Curr Signal Transd T 4 2009 122 129
42. C. Galustian, B. Meyer, M.C. Labarthe The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Cancer Immunol Immunother 58 2009 1033 1045
43. A.K. Abbas, K.M. Murphy, A. Sher Functional diversity of helper T lymphocytes Nature 383 1996 787 793 (Pubitemid 26372655)
44. G.P. Dunn, A.T. Bruce, H. Ikeda Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol 3 2002 991 998 (Pubitemid 35363648)
45. A.G. Dalgleish, K.J. O'Byrne Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer Adv Cancer Res 84 2002 231 276 (Pubitemid 34188199)
46. L. De Monte, M. Reni, E. Tassi Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer J Exp Med 208 2011 469 478
47. A.G. Heriot, J.B. Marriott, S. Cookson Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection Br J Cancer 82 2000 1009 1012 (Pubitemid 30128851)
48. J.X. Lin, W.J. Leonard Signaling from the IL-2 receptor to the nucleus Cytokine Growth Factor Rev 8 1997 313 332 (Pubitemid 28201656)
49. J.N. Blattman, J.M. Grayson, E.J. Wherry Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo Nat Med 9 2003 540 547 (Pubitemid 36597099)
50. O. Boyman, M. Kovar, M.P. Rubinstein Selective stimulation of T cell subsets with antibody-cytokine immune complexes Science 311 2006 1924 1927
51. F.O. Smith, S.G. Downey, J.A. Klapper Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines Clin Cancer Res 14 2008 5610 5618
52. J.A. Klapper, S.G. Downey, F.O. Smith High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006 Cancer 113 2008 293 301
53. D.J. Schwartzentruber, D.H. Lawson, J.M. Richards gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 364 2011 2119 2127
54. A.B. Alexandroff, A.M. Jackson, M.A. O'Donnell BCG immunotherapy of bladder cancer: 20 years on Lancet 353 1999 1689 1694 (Pubitemid 29224536)
55. W.M. Liu, D.W. Fowler, A.M. Gravett Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses Br J Cancer 105 2011 687 693
56. I.M. Orme, P. Andersen, W.H. Boom T cell response to Mycobacterium tuberculosis J Infect Dis 167 1993 1481 1497 (Pubitemid 23146211)
57. W.M. Liu, D.W. Fowler, P. Smith Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses Br J Cancer 102 2010 115 123
58. W.M. Liu, J.L. Dennis, D.W. Fowler The gene expression profile of un-stimulated dendritic cells can be used as a predictor of function Int J Cancer 130 2012 979 990
59. B. Seliger, F. Ruiz-Cabello, F. Garrido IFN inducibility of major histocompatibility antigens in tumors Adv Cancer Res 101 2008 249 276
60. J. Yang, Q. Yi Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules Cancer 116 2010 1638 1645
61. J. Copier, M. Bodman-Smith, A. Dalgleish Current status and future applications of cellular therapies for cancer Immunotherapy 3 2011 507 516
62. C. Du, Y. Wang The immunoregulatory mechanisms of carcinoma for its survival and development J Exp Clin Cancer Res 30 2011 12
63. W.J. Storkus, R.D. Salter, J. Alexander Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2 Proc Natl Acad Sci U S A 88 1991 5989 5992 (Pubitemid 21914871)
64. T. Cabrera, M.A. López-Nevot, J.J. Gaforio Analysis of HLA expression in human tumor tissues Cancer Immunol Immunother 52 2003 1 9 (Pubitemid 36177220)
65. N. Aptsiauri, T. Cabrera, R. Mendez Role of altered expression of HLA class I molecules in cancer progression Adv Exp Med Biol 601 2007 123 131
66. F. Garrido, T. Cabrera, A. Concha Natural history of HLA expression during tumour development Immunol Today 14 1993 491 499 (Pubitemid 23301000)
67. T.B. Tomasi, W.J. Magner, A.N. Khan Epigenetic regulation of immune escape genes in cancer Cancer Immunol Immunother 55 2006 1159 1184 (Pubitemid 43992044)
68. T. Rodríguez, R. Méndez, A. Del Campo Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines BMC Cancer 7 2007 34
69. R.A. Lake, B.W. Robinson Immunotherapy and chemotherapy - a practical partnership Nat Rev Cancer 5 2005 397 405 (Pubitemid 40637831)
70. D.M. Pardoll Inducing autoimmune disease to treat cancer Proc Natl Acad Sci U S A 96 1999 5340 5342 (Pubitemid 29234615)
71. J. Copier, A. Dalgleish Whole-cell vaccines: a failure or a success waiting to happen? Curr Opin Mol Ther 12 2010 14 20
72. S. Mocellin, S. Mandruzzato, V. Bronte Part I: vaccines for solid tumours Lancet Oncol 5 2004 681 689 (Pubitemid 40267853)
73. I.J. de Vries, W.J. Lesterhuis, N.M. Scharenborg Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients Clin Cancer Res 9 2003 5091 5100 (Pubitemid 37413557)
74. H. Jonuleit, U. Kühn, G. Müller Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions Eur J Immunol 27 1997 3135 3142 (Pubitemid 28018007)
75. M.V. Dhodapkar, R.M. Steinman, J. Krasovsky Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells J Exp Med 193 2001 233 238 (Pubitemid 32524454)
76. H. Jonuleit, E. Schmitt, G. Schuler Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells J Exp Med 192 2000 1213 1222
77. K.A. Noonan, A. Ferguson, A. Emerling Lenalidomide augments immune responses to Prevnar vaccination in relapsed myeloma patients: implications for cancer and infectious vaccines Blood (ASH Annual Meeting Abstracts) 114 2009 1864
78. G. Gonzalez, T. Crombet, F. Torres Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy Ann Oncol 14 2003 461 466 (Pubitemid 36367426)
79. E. Neninger, B.G. Verdecia, T. Crombet Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer J Immunother 32 2009 92 99
80. B. Grubeck-Loebenstein, S. Della Bella, A.M. Iorio Immunosenescence and vaccine failure in the elderly Aging Clin Exp Res 21 2009 201 209
81. Y. Hirooka, A. Itoh, H. Kawashima A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer Pancreas 38 2009 e69 e74
82. C. Bauer, F. Bauernfeind, A. Sterzik Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut 56 2007 1275 1282 (Pubitemid 47300430)
83. D. Toomey, H. Conroy, A.G. Jarnicki Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma Vaccine 26 2008 3540 3549